Cantor Fitzgerald Forecasts BMY FY2025 Earnings

Bristol-Myers Squibb (NYSE:BMY) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, April 22nd. Cantor Fitzgerald analyst C. Gould forecasts that the biopharmaceutical company will earn $6.81 per share for the year. Cantor Fitzgerald currently has a “Neutral” rating and a $55.00 target price on the stock. The consensus estimate for Bristol-Myers Squibb’s current full-year earnings is $6.74 per share.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.55 by $0.25. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The business had revenue of $11.20 billion for the quarter, compared to analysts’ expectations of $10.77 billion. During the same period last year, the business earned ($4.40) EPS.

A number of other brokerages also recently commented on BMY. Jefferies Financial Group decreased their price target on Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a research report on Wednesday. Piper Sandler began coverage on Bristol-Myers Squibb in a research note on Tuesday. They set an “overweight” rating and a $65.00 target price on the stock. The Goldman Sachs Group reissued a “neutral” rating and issued a $55.00 price target (down from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Citigroup lifted their price objective on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. Finally, Wells Fargo & Company increased their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a research report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $58.00.

Bristol-Myers Squibb Trading Down 1.7 %

Shares of BMY stock opened at $47.86 on Thursday. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33. The company has a 50-day simple moving average of $56.37 and a two-hundred day simple moving average of $56.47. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The company has a market capitalization of $97.38 billion, a price-to-earnings ratio of -10.83, a PEG ratio of 2.07 and a beta of 0.41.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in shares of Bristol-Myers Squibb by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 189,944,516 shares of the biopharmaceutical company’s stock valued at $10,743,262,000 after purchasing an additional 1,373,209 shares during the last quarter. Capital International Investors grew its position in Bristol-Myers Squibb by 7.5% during the fourth quarter. Capital International Investors now owns 45,866,624 shares of the biopharmaceutical company’s stock valued at $2,593,940,000 after acquiring an additional 3,218,865 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Bristol-Myers Squibb by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 44,391,247 shares of the biopharmaceutical company’s stock worth $2,505,967,000 after acquiring an additional 1,187,231 shares in the last quarter. Norges Bank bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth approximately $1,989,525,000. Finally, Ameriprise Financial Inc. boosted its stake in shares of Bristol-Myers Squibb by 59.9% in the 4th quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company’s stock valued at $1,814,341,000 after purchasing an additional 12,011,983 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Samit Hirawat bought 1,823 shares of the company’s stock in a transaction on Friday, February 14th. The stock was acquired at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the transaction, the executive vice president now directly owns 63,932 shares in the company, valued at $3,506,030.88. This trade represents a 2.94 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be given a dividend of $0.62 per share. The ex-dividend date is Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.18%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -56.11%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.